Project R-10649

Validation of age-associated B cells as therapeutic targets in MS (Research)

B cell depletion is a highly efficacious therapy for MS patients. However, the risks of long-term immune exhaustion urge for more specific and personalized treatment. Pro-inflammatory age-associated IgD-CD27- double negative (DN) B cells are abnormally elevated in MS patients. We are currently identifying the functional gene pathways that underlie the phenotype and function of DN B cells in MS patients. In this project, we aim to functionally validate the identified DN B cell targets in an animal model for MS and in a MS patient cohort study. This could ultimately lead to DN B cell specific targeting for MS treatment.

01 January 2020 - 31 December 2022